Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 70
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
Hepatol Res ; 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38877867

ABSTRACT

Chronic hepatitis B and C are among the most significant infectious diseases worldwide, and are major risk factors for liver cirrhosis and liver cancer. In Japan, comprehensive hepatitis measures are implemented for the testing and treatment of viral hepatitis, thus enabling the early diagnosis of liver cancer. Nevertheless, patients with decompensated cirrhosis and liver cancer often have unfavorable prognoses and require repetitive long-term treatment. In fiscal year 2018, an integrated policy of medical expense subsidies and research was established in Japan that aimed to alleviate patients' financial burden and launch the clinical registry of advanced liver disease. Over time, updates to the eligibility for the subsidy increased access to patients and has led to an increased number of beneficiaries. Additionally, the accumulation of clinical data in the registry has revealed the treatment choices for these diseases. However, the disparities in efforts across prefectures have also become evident. Raising public awareness of the policy and tightening the multisector healthcare network are keys to success in supporting qualifying patients with advanced liver disease.

2.
Gan To Kagaku Ryoho ; 48(12): 1491-1495, 2021 Dec.
Article in Japanese | MEDLINE | ID: mdl-34911917

ABSTRACT

It has been reported that preoperative rehabilitation reduces the risk of postoperative complications. We examined the factors impacting the efficacy of preoperative rehabilitation. Forty-three cancer patients who underwent abdominal surgery after preoperative rehabilitation at our hospital were assessed". Walkable"was defined as having the ability to walk to the toilet(distance>30 meters)without requiring support. Following the clinical path, if patients became"walkable"by the second day after surgery, they belonged to the smooth group, while the remaining patients belonged to the delayed group. We examined the factors influencing walking ability. The smooth group consisted of 34 patients(79%), and the delayed group consisted of 9 patients(21%). The significant factors related to delays in acquiring walking ability were old age and weakened lower limb function. Improving lower limb function through preoperative rehabilitation may lead to patients acquiring walking ability earlier after surgery, especially in older patients.


Subject(s)
Abdominal Neoplasms , Walking , Abdominal Neoplasms/surgery , Aged , Humans , Postoperative Complications
3.
Gan To Kagaku Ryoho ; 46(13): 2207-2209, 2019 Dec.
Article in Japanese | MEDLINE | ID: mdl-32156880

ABSTRACT

A 65-year-old woman underwent laparoscopic low anterior resection for rectal cancer with distant metastasis to the right lobe of her liver and mediastinal and right subclavian lymph nodes. Since the postoperative chemotherapy resulted in the disappearance of the lymph node metastasis and diminished hepatic metastasis lesion, the enlarged anterior segment of the liver was performed. She was administered chemotherapy for 1 year after the second surgery. Thoracoabdominal computed tomography performed 18 months after the end of the treatment revealed swelling of the left lobe of the thyroid. Ultrasonography showed a 23mm lobulated hypoechoic tumor in the left lobe of the thyroid gland. We suspected thyroid metastasis by aspiration biopsy cytology. Left thyroid lobectomy was performed for definitive diagnosis and local control. Histological examination revealed thyroid metastasis of the rectal cancer. We experienced a rare case of thyroid metastasis from rectal cancer.


Subject(s)
Rectal Neoplasms , Thyroid Neoplasms , Aged , Female , Humans , Lymphatic Metastasis , Thyroid Neoplasms/secondary , Thyroid Neoplasms/surgery , Thyroidectomy
4.
Pathol Int ; 67(8): 425-430, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28603942

ABSTRACT

We present a case of primary hepatic choriocarcinoma in an 83-year-old Japanese woman with gastric wall and lymph node metastases and a splenic vein tumor thrombus. Multiple irregular hepatic tumors with massive necrosis and hemorrhage were observed during autopsy. Syncytiotrophoblast-like and mononucleated cytotrophoblast-like cell morphology with focal hepatocellular carcinoma (HCC)-like trabecular structures was observed. In immunohistochemical analyses, the tumor cells expressed human chorionic gonadotropin (hCG) and cytokeratins (AE1/AE3, CK7, CK19) but were negative for alpha-fetoprotein (AFP), glypican-3, and vimentin. Immunohistochemical findings did not reveal evidence of HCC or angiosarcoma. We concluded the liver tumor was primary hepatic choriocarcinoma.


Subject(s)
Choriocarcinoma/pathology , Liver Neoplasms/pathology , Aged, 80 and over , Biomarkers, Tumor/analysis , Female , Humans
5.
Gan To Kagaku Ryoho ; 44(12): 1515-1517, 2017 Nov.
Article in Japanese | MEDLINE | ID: mdl-29394686

ABSTRACT

A 58-year-old man complaining of dysphagia was admitted to our hospital and diagnosed with esophageal cancer.He underwent thoracoscopic subtotal esophagectomy with 3-field lymph node dissection and reconstruction with a gastric tube created by hand-assisted laparoscopy.The pathological diagnosis was classified as AeLtG, pT3N2M0, pStage III .He was subsequently treated with systemic chemotherapy with 5-fluorouracil and cisplatin.After 2 courses, a single liver metastatic tumor appeared at segment 5.As chemotherapy against the recurrence, weekly-paclitaxel was administered.After 2 courses, the metastatic liver tumor reduced in size.Subsequently, laparoscopic partial liver resection was performed 11 months after first surgery.The pathological finding was negative for malignancy(pathological complete response).


Subject(s)
Esophageal Neoplasms/pathology , Liver Neoplasms/drug therapy , Paclitaxel/therapeutic use , Antineoplastic Agents, Phytogenic , Combined Modality Therapy , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/surgery , Esophagectomy , Humans , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Male , Middle Aged , Paclitaxel/administration & dosage , Prognosis
6.
Hepatogastroenterology ; 62(137): 169-74, 2015.
Article in English | MEDLINE | ID: mdl-25911890

ABSTRACT

BACKGROUND/AIMS: The aim of this study was determine the effectiveness of adjuvant S-1 chemotherapy for patients with resected pancreatic cancer. METHODOLOGY: Patients with pancreatic carcinoma who underwent pancreatic resection without adjuvant S-1 chemotherapy (n = 11) or with adjuvant S-1 chemotherapy (n = 10) were included. S-1 was administered orally at a dose of 40 mg/m2 twice daily for 28 consecutive days followed by a 14-day pause. The cycle was repeated 4 times. Overall and disease-free survival curves were generated using the Kaplan-Meier method, and statistical differences between groups were analyzed using the log-rank test. RESULTS: The disease-free survival and overall survival were longer among recipients of adjuvant S-1 chemotherapy than among those who received surgery alone (P < 0.05; 5-year disease-free survival rate, 30% versus 0%; 5-year overall survival rate, 65% vs 0%). Although dose reduction was needed in 2 patients because of grade 2 anorexia, only 1 patient with grade 2 hypoalbuminemia discontinued adjuvant chemotherapy because of long-term hospitalization. CONCLUSIONS: S-1 administered as a single agent showed promise as an adjuvant chemotherapy for resected pancreatic cancer.


Subject(s)
Adenocarcinoma/therapy , Antimetabolites, Antineoplastic/administration & dosage , Oxonic Acid/administration & dosage , Pancreatic Neoplasms/therapy , Pancreaticoduodenectomy , Tegafur/administration & dosage , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Aged , Aged, 80 and over , Antimetabolites, Antineoplastic/adverse effects , Chemotherapy, Adjuvant , Disease-Free Survival , Drug Administration Schedule , Drug Combinations , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Oxonic Acid/adverse effects , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Pancreaticoduodenectomy/adverse effects , Pancreaticoduodenectomy/mortality , Retrospective Studies , Risk Factors , Tegafur/adverse effects , Time Factors , Treatment Outcome
7.
Surg Today ; 45(7): 851-7, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25113072

ABSTRACT

PURPOSE: We evaluated the preoperative and postoperative characteristics and prognosis of super-elderly patients with hepatocellular carcinoma (HCC). METHODS: Four hundred and thirty-one patients who underwent hepatic resection for HCC were classified into three groups according to their age at the time of surgery: super-elderly (≥80 years; n = 20), elderly (70-80 years; n = 172) and younger (<70 years; n = 239). We compared the clinical characteristics, preoperative and postoperative factors and prognosis among the groups to evaluate whether liver resection is appropriate for super-elderly patients. RESULTS: The liver function was not significantly different among the groups. The proportion of patients with preoperative cardiovascular and respiratory disease and hypertension was higher in the super-elderly group compared to the other groups. The super-elderly group had shorter operations and reduced hemorrhage rates compared to the other groups. Postoperative cardiovascular complications and delirium were more frequently observed in the super-elderly group. The overall and tumor-free survival rates were not significantly different among the groups. Super-elderly patients had a lower rate of liver or HCC-related death and a higher rate of death due to other causes than the other groups. CONCLUSIONS: Super-elderly HCC patients who are appropriately evaluated and selected might have a favorable prognosis after undergoing hepatic resection.


Subject(s)
Carcinoma, Hepatocellular/surgery , Hepatectomy , Liver Neoplasms/surgery , Adult , Age Factors , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/mortality , Female , Humans , Liver Neoplasms/mortality , Male , Middle Aged , Postoperative Period , Preoperative Period , Prognosis , Risk Assessment , Survival Analysis , Treatment Outcome
8.
J Biol Chem ; 288(33): 23990-9, 2013 Aug 16.
Article in English | MEDLINE | ID: mdl-23843459

ABSTRACT

Protein-tyrosine phosphatase non-receptor type 23 (PTPN23) is a candidate tumor suppressor involved in the tumorigenesis of various organs. However, its physiological role(s) and detailed expression profile(s) have not yet been elucidated. We investigated the function and regulation of PTPN23 in the formation of testicular germ cell tumors (TGCTs). Expression of PTPN23 in human TGCT cell lines was significantly lower than that in spermatogonial stem cells in mice. Overexpression of PTPN23 in NEC8, a human TGCT cell line, suppressed soft agar colony formation in vitro and tumor formation in nude mice in vivo. These data indicate that PTPN23 functions as a tumor suppressor in TGCTs. Multiple computational algorithms predicted that the 3' UTR of human PTPN23 is a target for miR-142-3p. A luciferase reporter assay confirmed that miR-142-3p bound directly to the 3' UTR of PTPN23. Introduction of pre-miR-142 in the PTPN23 transfectant of NEC8 led to suppressed expression of PTPN23 and increased soft agar colony formation. Quantitative RT-PCR data revealed a significantly higher expression of miR-142-3p in human seminomas compared with normal testes. No difference in mRNA expression between seminoma and non-seminoma samples was detected by in situ hybridization. Both quantitative RT-PCR and immunohistochemical analyses revealed that PTPN23 expression was significantly lower in TGCTs than in normal testicular tissues. Finally, a lack of PTPN23 protein expression in human TGCTs correlated with a relatively higher miR-142-3p expression. These data suggest that PTPN23 is a tumor suppressor and that repression of PTPN23 expression by miR-142-3p plays an important role in the pathogenesis of TGCTs.


Subject(s)
MicroRNAs/metabolism , Neoplasms, Germ Cell and Embryonal/enzymology , Neoplasms, Germ Cell and Embryonal/genetics , Protein Tyrosine Phosphatases, Non-Receptor/metabolism , Testicular Neoplasms/genetics , Tumor Suppressor Proteins/metabolism , 3' Untranslated Regions/genetics , Animals , Base Sequence , Carcinogenesis/genetics , Carcinogenesis/pathology , Cell Line, Tumor , Cell Proliferation , Gene Expression Regulation, Neoplastic , Humans , Male , Mice , Molecular Sequence Data , Neoplasms, Germ Cell and Embryonal/pathology , Testicular Neoplasms/enzymology , Testicular Neoplasms/pathology , Testis/enzymology , Testis/pathology
9.
World J Surg Oncol ; 12: 12, 2014 Jan 13.
Article in English | MEDLINE | ID: mdl-24410788

ABSTRACT

We report a case of perivascular epithelioid cell tumor arising in the rectum of a 55-year-old woman. The tumor was treated by transanal endoscopic microsurgery. After 1 year follow-up, the patient is alive with no radiologic or endoscopic evidence of recurrence. Perivascular epithelioid cell tumor is a rare mesenchymal tumor characterized by co-expression of melanocytic and smooth muscle markers. This rare tumor can arise in various organs, including the falciform ligament, uterus, uterine cervix, liver, kidney, lung, breast, cardiac septum, pancreas, prostate, thigh, and gastrointestinal tract. Perivascular epithelioid cell tumor of the gastrointestinal tract is very rare, with only 23 previously reported cases. We review the literature on perivascular epithelioid cell tumors arising in the gastrointestinal tract.


Subject(s)
Perivascular Epithelioid Cell Neoplasms/pathology , Rectal Neoplasms/pathology , Female , Humans , Middle Aged , Perivascular Epithelioid Cell Neoplasms/surgery , Prognosis , Rectal Neoplasms/surgery
10.
Gastrointest Endosc ; 78(3): 476-83, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23622974

ABSTRACT

BACKGROUND: The discontinuation of antithrombotic drugs is recommended during endoscopic submucosal dissection (ESD) for gastric neoplasms; however, controversy remains as to whether antithrombotic drugs are risk factors for postoperative bleeding. OBJECTIVE: To determine the risk factors for post-ESD bleeding. DESIGN: Single-institution, retrospective review. SETTING: University hospital. PATIENTS: From June 2000 to December 2010, we treated 1192 gastric neoplasms in 1032 consecutive patients. INTERVENTION: The ESD procedures were performed by using the standard techniques. Antithrombotic drug therapy was principally interrupted preoperatively and was restarted when hemostasis was confirmed by second-look endoscopy. MAIN OUTCOME MEASUREMENTS: Risk factors for postoperative bleeding after ESD (early, delayed, and overall [combined] occurrence of bleeding during the first 5 postoperative days or thereafter) were analyzed by using logistic regression analysis. RESULTS: Among 1166 ESD-induced ulcer lesions, overall postoperative bleeding was evident in 62 lesions (5.3%); early and delayed bleeding occurred in 30 and 32 lesions (2.6% and 2.7%), respectively. Based on a multivariate analysis, a specimen size of >40 mm was the sole independent risk factor for overall bleeding. Moreover, oral antithrombotic drug therapy was selected as independent risk factor for delayed but not early bleeding, according to the multivariate analysis. The delayed bleeding rate in patients who had a specimen size of >40 mm and who used antithrombotic drugs was 11.6%. LIMITATIONS: Retrospective design and single-site data collection. CONCLUSION: Interruption of antithrombotic drug therapy may be adequate for preventing early post-ESD bleeding; however, reinitiating antithrombotic drug therapy is a significant independent risk factor for delayed post-ESD bleeding.


Subject(s)
Adenocarcinoma/surgery , Adenoma/surgery , Dissection/adverse effects , Fibrinolytic Agents/adverse effects , Postoperative Hemorrhage/etiology , Stomach Neoplasms/surgery , Adenocarcinoma/pathology , Adenoma/pathology , Aged , Female , Gastric Mucosa/surgery , Humans , Male , Middle Aged , Retrospective Studies , Risk Factors , Stomach Neoplasms/pathology , Time Factors
11.
Pathol Int ; 63(1): 45-55, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23356225

ABSTRACT

Birt-Hogg-Dubé syndrome (BHD) is an autosomal dominant disorder characterized by fibrofolliculomas, renal tumors and pulmonary cysts with repeated pneumothorax. This disorder is caused by mutations in the gene that encodes folliculin (FLCN). FLCN is known to be involved in the signaling of mammalian target of rapamycin (mTOR). We investigated the lung of a BHD patient who presented with a unique mutation. A 33-year-old woman visited our hospital due to repeated pneumothorax. Histopathologic study of the resected lung demonstrated multiple epithelial cysts. An increase of blood vessels was observed in the vicinity of subpleural cysts. Genomic DNA analysis revealed heterozygous mutation at the 3' end of intron 5 of the FLCN gene. Total mRNA and protein were extracted from the resected lung tissue. RT-PCR and sequence analysis demonstrated the production of exon 6-skipped FLCN mRNA. In Western blotting, the band intensities of phospho-mTOR, phospho-S6, phospho-Akt, hypoxia-inducible factor (HIF)-1α and vascular endothelial growth factor (VEGF) were increased in the BHD lung compared with normal lungs. Histopathologic analysis demonstrated strong immunostainings of mTOR signaling molecules in cyst-lining cells. Collective data indicates that dysregulation of mTOR signaling facilitates S6-mediated protein synthesis and HIF-1α-mediated angiogenesis, which may contribute to the development of pulmonary cysts in this disorder.


Subject(s)
Birt-Hogg-Dube Syndrome/genetics , Cysts/genetics , Lung Diseases/genetics , Mutation , Proto-Oncogene Proteins/genetics , TOR Serine-Threonine Kinases/metabolism , Tumor Suppressor Proteins/genetics , Adult , Birt-Hogg-Dube Syndrome/metabolism , Birt-Hogg-Dube Syndrome/pathology , Cysts/complications , Cysts/metabolism , Cysts/pathology , DNA Mutational Analysis , Female , Humans , Leukocytes, Mononuclear/chemistry , Leukocytes, Mononuclear/pathology , Lung/blood supply , Lung/pathology , Lung Diseases/metabolism , Lung Diseases/pathology , Neovascularization, Pathologic , Pneumothorax/etiology , Pneumothorax/genetics , Pneumothorax/metabolism , Pneumothorax/pathology , Proto-Oncogene Proteins/metabolism , Sequence Analysis, DNA , Signal Transduction , Tumor Suppressor Proteins/metabolism
12.
Surg Today ; 43(3): 276-83, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23052741

ABSTRACT

PURPOSE: Malnutrition has been considered a risk factor for the development of a surgical site infection (SSI). The aim of this study was to determine the relationship between preoperative nutritional screening scores and the development of SSI after pancreaticoduodenectomy. METHODS: We examined 64 patients who had undergone pancreaticoduodenectomy. Their clinical data, nutritional risk index (NRI), and nutritional risk screening 2002 (NRS-2002) score were recorded. SSIs were diagnosed according to the definitions of wound infection established by the Center for Disease Control and Prevention and were confirmed by a microbiological examination. Data were analyzed using the Fisher exact probability method and a multivariate logistic regression analysis. RESULTS: SSIs developed in 21 patients (33 %). Eleven patients had wound infections, and 14 patients had an intra-abdominal abscess. A univariate analysis of perioperative factors revealed that a pancreatic fistula, the NRS-2002, and the NRI were significantly associated with the development of SSI (p < 0.05). The multivariate logistic regression analysis revealed that a pancreatic fistula and the NRI were independent risk factors for SSI. By analyzing the pre- and intra-operative factors after excluding the 11 patients with pancreatic fistulas, the NRI was still an independent risk factor for SSI. CONCLUSION: The present study showed the NRI to be an independent factor for predicting the risk of SSI after pancreaticoduodenectomy.


Subject(s)
Malnutrition/complications , Nutrition Assessment , Risk Assessment/methods , Surgical Wound Infection/etiology , Adult , Aged , Aged, 80 and over , Female , Humans , Incidence , Japan/epidemiology , Male , Malnutrition/epidemiology , Middle Aged , Nutritional Status , Retrospective Studies , Risk Factors , Surgical Wound Infection/epidemiology , Survival Rate/trends , Young Adult
13.
Oncol Res ; 20(2-3): 71-9, 2012.
Article in English | MEDLINE | ID: mdl-23193913

ABSTRACT

Breast cancer is not a single entity. This study therefore aimed to identify differences in the impacts of anticancer agents and predictive factors between different breast cancer subtypes. A total of 234 patients with luminal (n = 109), luminal-HER2 (L-H, n = 29), HER-2 (n = 35), or triple negative (TN, n = 61) breast cancer subtypes were treated with standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane. Pathological response and prognosis were examined in each subtype. Expression levels of estrogen and progesterone receptors, HER-2, nuclear grade, MIB-1, p53, topoisomerase IIalpha (topoIIalpha), cytokeratin (CK) 5/6, and epidermal growth factor receptor (EGFR) were examined in association with quasipathological complete response (QpCR). QpCR rates were 9.1% (10/109) in luminal, 45% (13/29) in L-H, 37% (13/35) in HER2, and 54.1% (33/61) in TN. Non-QpCR patients showed significantly poorer 3-year disease-free survival than QpCR patients in TN, but not in patients with other subtypes. No factors were associated with QpCR in luminal patients. Patients with higher nuclear grade were more likely to achieve QpCR in L-H. The proliferative markers MIB-1 and topoIlalpha had opposite impacts on pathological response in HER-2 and TN. The QpCR rate was significantly higher in TN lacking CK5/6 and/or EGFR expression, defined as nonbasal subtype, compared with basal subtype (p = 0.049). Cytotoxic anticancer agents were associated with different responses in different breast cancer subtypes. Identifying basal-type cancer and further subdivision of nonbasal types is important for treating TN patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/classification , Breast Neoplasms/mortality , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Adult , Aged , Aged, 80 and over , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Female , Humans , Middle Aged , Prognosis , Remission Induction , Survival Rate , Young Adult
14.
Int J Gynecol Pathol ; 31(3): 227-35, 2012 May.
Article in English | MEDLINE | ID: mdl-22498939

ABSTRACT

Angiotensin II receptor-like 1 (APJ), a G protein-coupled receptor that was identified as a homologue of angiotensin II type 1 (AT1) receptor, exerts antagonistic effects on AT1-mediated vasoconstriction. Studies on pregnancy-induced hypertension (PIH) revealed aberrant activation of AT1 downstream signaling. In contrast, little is known about APJ in the pathophysiology of human pregnancy. In this study, we investigated APJ expression in normal human and PIH placentas. mRNAs were extracted from 50 placental villous tissues of 18 cases with severe PIH (8 late-onset, 4 early-onset, and 6 superimposed PIH) and 32 control pregnancies (including 6 preterm cases). Histopathologic studies were conducted using paraffin-embedded placental tissues from 12 control placentas (from 23 to 39 wk) and 23 PIH placentas (from 24 to 41 wk). Reverse transcriptase-polymerase chain reaction showed that APJ was cooperatively expressed with its ligand apelin and AT1 in controls and in late-onset PIH placentas but was significantly downregulated in early-onset PIH placentas with poor fetal growth. Quantitative reverse transcriptase-polymerase chain reaction analysis revealed upregulated APJ in late-onset PIH placentas but significantly downregulated APJ in early-onset PIH. In immunohistochemical staining, APJ was detected strongly in villous capillary endothelial cells and trophoblasts of late-onset PIH placentas. In contrast, APJ was poorly stained in endothelial cells of hypoplastic villi of early-onset PIH placentas. Collective data indicate that the apelin-APJ system is involved in fetoplacental circulation during human pregnancy. Impaired APJ expression in early-onset PIH placentas may reflect an aggravated placental condition with poor fetal growth.


Subject(s)
Hypertension/metabolism , Placenta/metabolism , Placenta/pathology , Pregnancy Complications, Cardiovascular/metabolism , RNA, Messenger/metabolism , Receptors, G-Protein-Coupled/metabolism , Apelin , Apelin Receptors , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Female , Gestational Age , Humans , Hypertension/etiology , Intercellular Signaling Peptides and Proteins/metabolism , Pregnancy , Receptor, Angiotensin, Type 1/metabolism , Retrospective Studies , Severity of Illness Index , Signal Transduction/physiology , Trophoblasts/metabolism , Trophoblasts/pathology
15.
Hepatogastroenterology ; 59(116): 1010-2, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22580650

ABSTRACT

BACKGROUND/AIMS: We aimed to clarify the surgical indication and describe the long-term surgical outcome for ampullary carcinoma. METHODOLOGY: The long-term outcomes of 23 patients who underwent pancreaticoduodenectomy were retrospectively reviewed. The prognostic factors for cancer-specific survival and overall survival after surgery were investigated. RESULTS: The cancer-specific 5-, 10- and 20-year survival rates after resection of the ampullary carcinoma were 52%, 43% and 43%, respectively, while the corresponding overall survival rates were 52%, 32% and 24%, respectively. Ten of the 11 patients with recurrent ampullary carcinoma died within 5 years after surgery. Four patients died because of pancreatic cancer, colon cancer, old age after curative resection of gastric cancer, and pneumonia at later than 5 years after the surgery. The risk factors for the short cancer-specific survival period were pancreatic invasion and lymph node metastasis, while those for the short overall survival period were pancreatic invasion and the tumor grade. CONCLUSIONS: Our study indicates that recurrence of ampullary carcinoma within 5 years after its resection, especially in patients with pancreatic invasion or lymph node metastasis and development of other diseases after more than 5 years after the surgery should be carefully investigated.


Subject(s)
Ampulla of Vater/surgery , Common Bile Duct Neoplasms/surgery , Pancreaticoduodenectomy , Aged , Common Bile Duct Neoplasms/mortality , Common Bile Duct Neoplasms/pathology , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Retrospective Studies , Survival Rate , Treatment Outcome
16.
Gastrointest Endosc ; 74(6): 1268-75, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22015001

ABSTRACT

BACKGROUND: Endoscopic submucosal dissection (ESD) was introduced worldwide as a new treatment option for early gastric cancer, but curability prediction has not been evaluated on an individual basis. OBJECTIVE: To analyze factors contributing to the curability of early gastric cancer after ESD and to construct a risk assessment chart for the probability of curability. DESIGN: Single-institution retrospective review. SETTING: University hospital. PATIENTS: From June 2000 to April 2010, we treated 961 early gastric cancers in 784 patients (mean age 70.2 years). INTERVENTION: ESD procedures were performed using typical sequences. MAIN OUTCOME MEASUREMENTS: Risk factors related to resectability (en bloc or piecemeal resection) and curability (curative or noncurative resection) after ESD were analyzed using logistic regression analysis. Using this model, we constructed a risk assessment chart to predict the probability of noncurability from patient characteristics. RESULTS: The en bloc and curative resection rates were 98.9% and 88.1%, respectively, after ESD. Significant contributors to noncurative ESD were large lesions, upper location, and ulcer findings. Predicted noncurability probabilities were displayed in 4 colors for each risk level (light blue, blue, yellow, and red) by combining tumor size, tumor location, and ulcer findings. Probability of noncurability was highest (≥ 40%) in ulcerative large tumors (>30 mm in diameter) in the upper location (red) and lowest in nonulcerative small tumors (≤ 20 mm in diameter) in the lower location (light blue). LIMITATIONS: Retrospective design and single-site data collection. CONCLUSIONS: This risk assessment chart shows individuals their pretreatment curability assessment with successful ESD and may be an educational tool for trainees or a decision-making tool.


Subject(s)
Dissection/methods , Gastric Mucosa/surgery , Gastroscopy/methods , Neoplasm Recurrence, Local/epidemiology , Neoplasm Staging , Risk Assessment/methods , Stomach Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Early Diagnosis , Female , Follow-Up Studies , Gastric Mucosa/pathology , Humans , Male , Middle Aged , Retrospective Studies , Stomach Neoplasms/pathology , Time Factors , Treatment Outcome
17.
Nihon Kokyuki Gakkai Zasshi ; 49(9): 667-73, 2011 Sep.
Article in Japanese | MEDLINE | ID: mdl-22073613

ABSTRACT

We recently experienced one each of 2 types of recurrent respiratory papillomatosis (RRP). Case 1 (juvenile-onset type): A 30-year-old woman presenting with bloody sputum and large tumors with cavities on her chest Xray film, was referred to our hospital. She had been diagnosed with laryngeal papillomatosis when she was three years old. According to our bronchoscopical examination biopsy, she was diagnosed with squamous cell carcinoma of the lung in addition to papillomatosis of the trachea and bronchus. Although chemotherapy was performed, she died 2 years after the diagnosis of lung cancer without any distinct treatment efficacy. Case 2 (adult-onset type): A 43 year-old woman presenting with fever and dry cough visited our hospital. Chest CT revealed that there was narrowing of bilateral main bronchi and hilar lymphadenopathy. Bronchoscopic examination revealed diffuse papilloma distributed extensively from the trachea to bilateral main bronchi. However, she recovered spontaneously in 6 months and has remained stable without recurrence. Both cases were diagnosed with RRP based on the separation of HPV in case 1 and pathological findings of koilocytosis in case 2. Case 1 was complicated with squamous cell carcinoma of the lung in the clinical course, presumably due to occurrence of malignant conversion of papillomatosis. Since RRP is a rare but refractory disease, novel effective treatment is necessary.


Subject(s)
Papillomavirus Infections/diagnosis , Respiratory Tract Infections/diagnosis , Adult , Carcinoma, Squamous Cell/complications , Female , Humans , Lung Neoplasms/complications , Papillomaviridae/isolation & purification , Papillomavirus Infections/pathology , Papillomavirus Infections/virology , Respiratory Tract Infections/pathology , Respiratory Tract Infections/virology
18.
Gastrointest Endosc ; 72(5): 960-6, 2010 Nov.
Article in English | MEDLINE | ID: mdl-21034897

ABSTRACT

BACKGROUND: Endoscopic submucosal dissection (ESD) was recently introduced as a treatment option for superficial adenocarcinoma of the esophagogastric junction (EGJ); however, its long-term clinical outcomes have not been fully evaluated. OBJECTIVE: To assess the long-term outcomes of ESD for patients with superficial adenocarcinoma of the EGJ. DESIGN: Retrospective review from a single institution. SETTING: University hospital. PATIENTS: Fifty-eight patients, 46 men and 12 women (mean 69.3 years), with 39 T1m and 19 T1sm adenocarcinomas of the EGJ treated from June 2000 to May 2009. INTERVENTIONS: ESD procedures were performed with typical sequences. MAIN OUTCOME MEASUREMENTS: Complications, en bloc resection rate, curative resection rate, local recurrence, and distant metastases after ESD were evaluated. Curative resection is histologically defined as being free of resection margins and any evidence of deep submucosal invasion, undifferentiated carcinoma, and lymphovascular invasion. RESULTS: There were no major complications except for 3 patients with ulcer bleeding without the need for blood transfusion and 1 patient with esophageal stenosis. The rates of en bloc resection and curative resection were 100% and 79%, respectively. Twelve resections were histologically considered noncurative; these patients underwent additional ESD (n = 1) or surgical resection (n = 8). Local or distant recurrences were not observed in any patient achieving curative resection during follow-up (median 36.6 months, range 4-94 months). LIMITATIONS: Retrospective design and single-site data collection. CONCLUSIONS: Long-term outcomes after ESD are favorable. ESD may be adopted as a treatment of choice for superficial adenocarcinoma of the EGJ.


Subject(s)
Adenocarcinoma/surgery , Dissection , Endoscopy, Gastrointestinal , Esophageal Neoplasms/surgery , Esophagogastric Junction , Adenocarcinoma/pathology , Adult , Aged , Aged, 80 and over , Cohort Studies , Esophageal Neoplasms/pathology , Female , Humans , Male , Middle Aged , Mucous Membrane/surgery , Retrospective Studies , Treatment Outcome
19.
J Vasc Interv Radiol ; 21(11): 1716-24, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20884228

ABSTRACT

PURPOSE: To assess the extended effects of transcatheter arterial embolization with iodized oil and gelatin sponge on liver histopathologic changes in radiofrequency (RF)-ablated zones and the surrounding liver parenchyma in a pig model. MATERIALS AND METHODS: Eighteen consecutive pigs subjected to 36 RF applications performed immediately after segmental embolization with iodized oil and gelatin sponge to the left lobe of the liver (embolization/RF ablation) were euthanized immediately after the procedure or 1 or 4 weeks later. The right lobes were used as controls for RF applications without embolization. The ablated zones and the surrounding liver parenchyma were measured and examined histopathologically. RESULTS: The average maximum ablated zone was significantly larger in the embolization/RF ablation specimens than in the RF ablation-alone specimens at all three follow-up time points. Ten of the 12 specimens obtained immediately after embolization/RF ablation showed wide hemorrhagic areas spreading to the periphery of the liver and microscopically showed marked intralobular congestion with sinusoidal dilation. This hemorrhagic change had disappeared in all the specimens obtained 1 week after embolization/RF ablation, but 10 of the 12 specimens showed wedge-shaped areas of segmental degenerative parenchyma beginning at the ablated zone and extending to the periphery of the liver; these were microscopically revealed to be areas of coagulative necrosis, indicating hepatic infarction. The sizes of these necrotic zones had decreased at 4 weeks after embolization/RF ablation. CONCLUSIONS: RF ablation performed immediately after embolization in normal pig liver induced large ablated zones accompanied by wedge-shaped areas of segmental infarction.


Subject(s)
Catheter Ablation , Embolization, Therapeutic/methods , Gelatin Sponge, Absorbable/administration & dosage , Iodized Oil/administration & dosage , Liver/surgery , Animals , Blood Coagulation , Female , Liver/blood supply , Liver/pathology , Models, Animal , Necrosis , Sus scrofa , Time Factors
20.
Jpn J Clin Oncol ; 40(7): 620-6, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20299497

ABSTRACT

OBJECTIVE: We investigated the pathological effects of neoadjuvant chemotherapy based on the human epidermal growth factor receptor 2 in operable breast cancer. METHODS: This prospective clinical study was a pilot involving 63 female patients. Before surgery, patients with tumors overexpressing human epidermal growth factor receptor 2 received four cycles of 60 mg/m(2) anthracycline and 600 mg/m(2) cyclophosphamide every 3 weeks, whereas those whose tumors did not overexpress human epidermal growth factor receptor 2 received four cycles of 75 mg/m(2) docetaxel and 600 mg/m(2) cyclophosphamide every 3 weeks. A quasi-pathological complete response (i.e. absence of invasive tumor or only focal residual tumor cells) was the primary endpoint, with compliance and predictors for each regimen as secondary endpoints. If a quasi-pathological complete response was not achieved, then crossover to the alternative treatment was recommended. RESULTS: The quasi-pathological complete response rate was 36.5% (23 of 63) overall, 27.8% (5 of 18) for the anthracycline and cyclophosphamide regimen and 40.0% (18 of 45) for the docetaxel and cyclophosphamide regimen. Docetaxel and cyclophosphamide treatment induced a quasi-pathological complete response in most patients with triple-negative tumors (15 of 19). The relative dose intensity was 97.3% for the anthracycline and cyclophosphamide regimen and 96.6% for the docetaxel and cyclophosphamide regimen. Quasi-pathological complete response to the docetaxel and cyclophosphamide regimen was associated with low estrogen receptor and progesterone receptor expression and high MIB-1 and topoisomerase IIalpha expression, in univariate analyses, but only with low estrogen receptor expression in multivariate analysis. CONCLUSIONS: Selecting neoadjuvant chemotherapy regimens on the basis of individual human epidermal growth factor receptor 2 status improved efficacy, with docetaxel and cyclophosphamide treatment showing particular promise in tumors with the potential to be highly malignant.


Subject(s)
Breast Neoplasms/drug therapy , Neoadjuvant Therapy , Receptor, ErbB-2/metabolism , Adolescent , Adult , Aged , Anthracyclines/therapeutic use , Antineoplastic Agents/therapeutic use , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Cyclophosphamide/therapeutic use , Docetaxel , Female , Humans , Middle Aged , Taxoids/therapeutic use , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL